Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$184.9 million.

  • BridgeBio Pharma's Income from Continuing Operations fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$763.1 million, marking a year-over-year decrease of 85.40%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Income from Continuing Operations is -$184.9 million, which was down 9.04% from -$169.6 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Income from Continuing Operations peaked at -$19.1 million during Q1 2024, and registered a low of -$267.4 million during Q4 2024.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$164.3 million (2024), whereas its average is -$150.3 million.
  • Per our database at Business Quant, BridgeBio Pharma's Income from Continuing Operations spiked by 86.59% in 2024 and then tumbled by 640.71% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Income from Continuing Operations (Quarterly) stood at -$180.6 million in 2021, then climbed by 19.62% to -$145.1 million in 2022, then plummeted by 32.37% to -$192.1 million in 2023, then plummeted by 39.19% to -$267.4 million in 2024, then dropped by 12.59% to -$184.9 million in 2025.
  • Its Income from Continuing Operations was -$184.9 million in Q3 2025, compared to -$169.6 million in Q2 2025 and -$141.1 million in Q1 2025.